GlassScriptPhysician profile
Tanaz Kahen
NPI 1679542898
$16,609.27
in general payments reported to CMS, 2019-2025
30 companies · $7,014 in 2025
The $7,014 reported for 2025 was more than what 98% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $735 · 2020: $690 · 2021: $1,242 · 2022: $1,133 · 2023: $881 · 2024: $4,915 · 2025: $7,014.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Food and Beverage: $2,210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,600.00 |
| Food and Beverage | $2,210.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $10,623.78 | 2024-2025 | Bovine Collagen |
| Abbvie INC. | $1,847.13 | 2019-2024 | |
| Pfizer INC. | $585.98 | 2020-2025 | |
| Mayne Pharma Commercial LLC | $582.17 | 2021-2025 | |
| Hologic Sales and Service, LLC | $436.01 | 2019-2025 | Aptima, Thinprep 2000 Processor, Acessa Provu System |
| Myovant Sciences INC. | $296.48 | 2021-2022 | |
| Exeltis, USA INC. | $280.90 | 2019-2025 | Slynd |
| Sumitomo Pharma America, INC. | $274.28 | 2023-2025 | Myfembree |
| Therapeuticsmd, INC. | $267.75 | 2019-2022 | |
| Evofem Biosciences, INC. | $224.10 | 2020-2025 | Phexxi, Solosec, Phexx |
| Allergan, INC. | $171.74 | 2019-2020 | |
| Organon LLC | $121.95 | 2024 | |
| Coopersurgical, INC. | $119.27 | 2025 | Paragard T 380a |
| Avion Pharmaceuticals | $114.02 | 2020 | |
| Sage Therapeutics, LLC | $90.11 | 2024-2025 | Zurzuvae |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lupin INC. | $80.00 | 2019-2021 | |
| Amag Pharmaceuticals, INC. | $67.35 | 2019 | |
| Myriad Women'S Health, INC. | $66.51 | 2023 | Myrisk |
| Millicent US INC | $66.24 | 2024-2025 | Intrarosa, Femlyv, Femring |
| Bayer Healthcare Pharmaceuticals INC. | $42.75 | 2019-2020 | |
| Lucid Diagnostics INC. | $35.38 | 2022-2023 | |
| Astellas Pharma US INC | $34.21 | 2025 | Veozah |
| Becton, Dickinson and Company | $32.75 | 2019 | |
| Exact Sciences Corporation | $24.43 | 2025 | Cologuard Collection Kit |
| Duchesnay USA Incorporated | $24.35 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.35 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $20.52 | 2021 | |
| Roche Diagnostics Corporation | $19.77 | 2019 | |
| Agile Therapeutics, INC. | $18.98 | 2024 | Twirla |
| Boston Scientific Corporation | $18.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tanaz Kahen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.